摘要
目的探讨多西他赛、顺铂及替吉奥方案(TPS)诱导化疗序贯同期放化疗治疗局部晚期鼻咽癌的疗效和安全性。方法对收治的35例局部晚期鼻咽癌患者进行回顾分析。所有患者均完成3周期TPS方案(第1天多西他赛60 mg/m^(2)+第1天顺铂60 mg/m^(2)+第1~14天替吉奥60 mg/m^(2),2次/d口服,每21 d为1个周期)诱导化疗后序贯同期放化疗,评价临床疗效、平均住院时间和安全性。结果 TPS诱导化疗后,近期疗效评估示完全缓解率11.4%、客观缓解率88.6%,远期疗效评估示3年无进展生存率82.9%、3年总生存率91.4%。诱导化疗期间住院时间(3.2±0.5)d。整个治疗期间最常见的严重不良反应为3~4级白细胞减少,发生率为28.5%。结论 TPS方案用于局晚鼻咽癌的诱导化疗,可能具有与TPF方案相当的疗效和更好的安全性,且该方案应用更便利,有利于加快病房周转,值得进一步研究。
Objective To investigate the efficacies and toxicities of docetaxel, cisplatin and S-1(TPS) as induction chemotherapy followed by concurrent chemoradiotherapy for patients with local advanced nasopharyngeal carcinoma. Methods A retrospective analysis was performed on the selected 35 cases of patients with local advanced nasopharyngeal carcinoma. All the patients received 3 cycles of TPS induction chemotherapy followed by concurrent chemoradiotherapy. The efficacy, length of stay and toxicities were evaluated. Results CR rate and objective response rate(ORR) after TPS induction chemotherapy were 11.4% and 88.6%, respectively. The progression-free and overall survival at 3 years were 82.9% and 91.4%, respectively. The length of stay during TPS regimen was(3.2±0.5) days. The rate of Grade 3-4 of leukopenia was 28.5%, which was the most common serious adverse effect. Conclusion Campared with TPF regimen, TPS as induction chemotherapy for patients with local advanced nasopharyngeal carcinoma may have equal efficacy and higher safety. And TPS regimen is more convenient, which is in favor of hospital bed turnover.
作者
廖恺
郑荣辉
陶昊昀
詹泽江
冯建辉
谭锦云
LIAO Kai;ZHENG Rong-hui;TAO Hao-yun;ZHAN Ze-jiang;FENG Jian-hui;TAN Jin-yun(Department of Radliotherapy,Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,Guangdong,China)
出处
《广东医学》
CAS
2021年第1期76-79,共4页
Guangdong Medical Journal
基金
广东省科技计划项目(2018B070702005)
广州医科大学博士启动基金资助项目(2016C37)。
关键词
鼻咽癌
诱导化疗
多西他赛
顺铂
替吉奥
nasopharyngeal carcinoma
induction chemotherapy
docetaxel
cisplatin
S-1
